Biological characterization with CSF proteomics of dementia with Lewy bodies (DLB) according Alzheimer's disease (AD) biomarker profile

In dementia with Lewy bodies (DLB), Alzheimer co‐pathology is common, and associated with an unfavorable prognosis. For targeted treatment development it is crucial to understand the biological underpinnings of DLB with Alzheimer co‐pathology, and how it differs from Alzheimer disease (AD). We performed a cerebrospinal fluid (CSF) proteome profiling to biologically characterize DLB with and without AD co‐pathology in vivo.